U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H7NO3
Molecular Weight 153.1354
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AMINOSALICYLIC ACID

SMILES

NC1=CC(O)=C(C=C1)C(O)=O

InChI

InChIKey=WUBBRNOQWQTFEX-UHFFFAOYSA-N
InChI=1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)

HIDE SMILES / InChI
Molecular Formula C7H7NO3
Molecular Weight 153.1354
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including http://www.rxlist.com/paser-drug.htm

4-AMINOSALICYLIC ACID (Paser) is an anti-tuberculosis drug used to treat tuberculosis in combination with other active agents. 4-AMINOSALICYLIC ACID (Paser) is most commonly used in patients with Multi-drug Resistant TB (MDR-TB) or when isoniazid and rifampin use is not possible due to a combination of resistance and/or intolerance. There are two mechanisms responsible for aminosalicylic acid's bacteriostatic action against Mycobacterium tuberculosis. Firstly, aminosalicylic acid inhibits folic acid synthesis (without potentiation with antifolic compounds). The binding of para-aminobenzoic acid to pteridine synthetase acts as the first step in the folic acid synthesis. Aminosalicylic acid binds pteridine synthetase with greater affinity than para-aminobenzoic acid, effectively inhibiting the synthesis of folic acid. As bacteria are unable to use external sources of folic acid, cell growth and multiplication slow. Secondly, the aminosalicylic acid may inhibit the synthesis of the cell wall component, mycobactin, thus reducing iron uptake by M. tuberculosis.

CNS Activity

CNS Non-penetrant
1014
Curator's Comment: In humans CSF penetration occurs only if the meninges is inflamed. Shown to be CNS penetrant in mouse http://www.nature.com/aps/journal/vaop/ncurrent/pdf/aps2014103a.pdf

Originator

Lehmann, J.
6
Curator's Comment: In 1943 Jorgen Lehmann, a Swedish physician, developed para-aminosalicylic acid (PASCAINE). Lehmann first tried PAS as an oral TB therapy late in 1944.

Approval Year

1948
95
Targets

Targets

Primary TargetPharmacologyConditionPotency
Inhibitor
8297
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
PASER

Approved Use

Tuberculosis

Launch Date

1994
Primary
Phase II
1132
PASER

Approved Use

Unknown

Launch Date

1994
Primary
Phase II
1132
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
53.63 mg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31682027/
4 g 2 times / day multiple, oral
dose: 4 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMINOSALICYLIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
82.69 mg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31682027/
8 g 1 times / day multiple, oral
dose: 8 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMINOSALICYLIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
20 μg/mL
DRUG LABEL
https://www.ema.europa.eu/en/documents/product-information/granupas-epar-product-information_en.pdf
4 g single, oral
dose: 4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
AMINOSALICYLIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
16.36 mg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31682027/
8 g 1 times / day multiple, oral
dose: 8 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
4-ACETAMIDOSALICYLIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
14.59 mg/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31682027/
4 g 2 times / day multiple, oral
dose: 4 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
4-ACETAMIDOSALICYLIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
414.07 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31682027/
4 g 2 times / day multiple, oral
dose: 4 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMINOSALICYLIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
690.35 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31682027/
8 g 1 times / day multiple, oral
dose: 8 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
AMINOSALICYLIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
142.49 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31682027/
8 g 1 times / day multiple, oral
dose: 8 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
4-ACETAMIDOSALICYLIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
145.02 mg × h/L
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/31682027/
4 g 2 times / day multiple, oral
dose: 4 g
route of administration: Oral
experiment type: MULTIPLE
co-administered:
4-ACETAMIDOSALICYLIC ACID plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.62 h
DRUG LABEL
https://www.ema.europa.eu/en/documents/product-information/granupas-epar-product-information_en.pdf
4 g single, oral
dose: 4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
AMINOSALICYLIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
45%
DRUG LABEL
https://www.ema.europa.eu/en/documents/product-information/granupas-epar-product-information_en.pdf
4 g single, oral
dose: 4 g
route of administration: Oral
experiment type: SINGLE
co-administered:
AMINOSALICYLIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9052519
Page: p.356
unhealthy, 45.5
n = 23
Health Status: unhealthy
Condition: Ulcerative colitis
Age Group: 45.5
Sex: M+F
Population Size: 23
Sources:
https://pubmed.ncbi.nlm.nih.gov/9052519
Page: p.356
Disc. AE: Dyspepsia, Lipase increased...
AEs leading to
discontinuation/dose reduction:
Dyspepsia (severe, 4.3%)
Lipase increased (4.3%)
Aspartate aminotransferase abnormal (4.3%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9052519
Page: p.356
4 g 3 times / day multiple, oral
Recommended
Dose: 4 g, 3 times / day
Route: oral
Route: multiple
Dose: 4 g, 3 times / day
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6f2753dc-5f0c-4f49-9335-e519afb69ba6&type=display
unhealthy
n = 7492
Health Status: unhealthy
Condition: Tuberculosis
Sex: M+F
Population Size: 7492
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6f2753dc-5f0c-4f49-9335-e519afb69ba6&type=display
Disc. AE: Drug-induced hepatitis...
AEs leading to
discontinuation/dose reduction:
Drug-induced hepatitis (0.5%)
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6f2753dc-5f0c-4f49-9335-e519afb69ba6&type=display
AEs

AEs

AESignificanceDosePopulation
Aspartate aminotransferase abnormal 4.3%
Disc. AE
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9052519
Page: p.356
unhealthy, 45.5
n = 23
Health Status: unhealthy
Condition: Ulcerative colitis
Age Group: 45.5
Sex: M+F
Population Size: 23
Sources:
https://pubmed.ncbi.nlm.nih.gov/9052519
Page: p.356
Lipase increased 4.3%
Disc. AE
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9052519
Page: p.356
unhealthy, 45.5
n = 23
Health Status: unhealthy
Condition: Ulcerative colitis
Age Group: 45.5
Sex: M+F
Population Size: 23
Sources:
https://pubmed.ncbi.nlm.nih.gov/9052519
Page: p.356
Dyspepsia severe, 4.3%
Disc. AE
3 g 2 times / day multiple, oral
Highest studied dose
Dose: 3 g, 2 times / day
Route: oral
Route: multiple
Dose: 3 g, 2 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9052519
Page: p.356
unhealthy, 45.5
n = 23
Health Status: unhealthy
Condition: Ulcerative colitis
Age Group: 45.5
Sex: M+F
Population Size: 23
Sources:
https://pubmed.ncbi.nlm.nih.gov/9052519
Page: p.356
Drug-induced hepatitis 0.5%
Disc. AE
4 g 3 times / day multiple, oral
Recommended
Dose: 4 g, 3 times / day
Route: oral
Route: multiple
Dose: 4 g, 3 times / day
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6f2753dc-5f0c-4f49-9335-e519afb69ba6&type=display
unhealthy
n = 7492
Health Status: unhealthy
Condition: Tuberculosis
Sex: M+F
Population Size: 7492
Sources:
https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=6f2753dc-5f0c-4f49-9335-e519afb69ba6&type=display
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer
P-gp
1461
P-gp
1537

MRP1
107

OATP1B1
406

OCT1
327

OCT2
355

OAT1
326

OAT3
339
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
P-gp
1650
 yes [IC50 1.94 uM]
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
MRP1
107
 yes
OAT1
326
 yes
OAT3
339
 yes
OATP1B1
406
 yes
OCT1
327
 yes
OCT2
355
 yes
P-gp
1537
 yes
Sourcing

Sourcing

Vendor/AggregatorIDURL
001 Chemical
NO22593
https://www.001chemical.com/chem/65-49-6
3B Scientific (Wuhan) Corp
3B3-030325
http://www.3bsc.com/index/pro_info.php?id=51589
AA Blocks
AA003KPD
https://www.aablocks.com/goods/Goods/detail?id=AA003KPD
AHH Chemical co.,ltd
MT-01909
http://www.ahhchemical.com/product/MT-01909.html
AK Scientific, Inc. (AKSCI)
65768
http://www.aksci.com/item_detail.php?cat=65768
Aaron Chemicals
AR003LH5
http://www.aaronchem.com/65-49-6
Acadechem
ACDS-017148
http://www.acadechemical.com/product/91847
Accela ChemBio Inc
SY001079
http://www.accelachem.com/cn/search.html?keyword=SY001079&attname=GoodsCode
Aceschem
ACS013053
https://www.aceschem.com/catalog/65-49-6.html
Achemica
ACMC-1BIVG
http://www.achemica.com/prodinfo/?id=54760
Achemo Scientific Limited
AC-22808
http://www.achemo.com/search/?Keyword= 65-49-6
Achemtek
0104-029388
http://www.achemtek.com/65-49-6
Acros Organics
AC104620050
https://www.fishersci.com/shop/products/4-aminosalicylic-acid-99-acros-organics/AC104620050
Acros Organics
AC104621000
https://www.fishersci.com/shop/products/4-aminosalicylic-acid-99-acros-organics/AC104621000
Acros Organics
AC104625000
https://www.fishersci.com/shop/products/4-aminosalicylic-acid-99-acros-organics/AC104625000
Alfa Aesar
B23289
https://www.alfa.com/en/catalog/B23289/
Alfa Chemistry
AP65496-A
https://reagents.alfa-chemistry.com/product/4-aminosalicylic-acid-cas-65-49-6-14694.html
Alfa Chemistry
AP65496-B
https://reagents.alfa-chemistry.com/product/aminosalicylic-acid-cas-65-49-6-14695.html
Ambinter
Amb1215242
http://www.ambinter.com/reference/1215242
Anward
ANW-35052
http://www.anward.com/pro_result/15246
Ark Pharm
AK-46320
http://www.arkpharminc.com/products/65-49-6.html
Aurora Fine Chemicals LLC
A00.158.421
http://online.aurorafinechemicals.com/info?ID=A00.158.421
Aurum Pharmatech LLC
H2354
http://www.Aurumpharmatech.com/Product/ProductDetails/H2354
Aurum Pharmatech LLC
M-5913
http://www.Aurumpharmatech.com/Product/ProductDetails/M_5913
Avantor Inc
200029-596
https://us.vwr.com/store/product/7513678/4-aminosalicylic-acid
Avantor Inc
101094-038
https://us.vwr.com/store/product/7889339/4-aminosalicylic-acid
BLD Pharm
BD94285
http://www.bldpharm.com/products/65-49-6.html
BenchChem
B518644
https://www.benchchem.com/product/b518644
BioChemPartner
BCP18565
http://www.biochempartner.com/65-49-6-BCP18565
BioCrick
BCC8691
http://www.biocrick.com/4-Aminosalicylic-acid-BCC8691.html
BioSynth
Q-200437
https://www.biosynth.com/en/products/chemical-intermediates/basic-intermediates/products/Q-200437.html
Boerchem
BC205364
http://www.boerchem.com/?product_34572.html
CSNpharm
CSN23620
https://www.csnpharm.com/products/4-aminosalicylic-acid.html
Capot Chemical
23542
http://www.capotchem.com/en/23542.htm
Capot Chemical
PubChem23542
http://www.capotchem.com/en/23542.htm
Chem Scene
CS-W023102
http://www.chemscene.com/65-49-6.html
ChemFish Tokyo co.,ltd
4649
http://www.chemfish.co.jp/index.php?id=5063&project=product
ChemMol
30102576
http://www.chemmol.com/chemmol/30102576.html
ChemMol
44002107
http://www.chemmol.com/chemmol/44002107.html
ChemMol
99122203
http://www.chemmol.com/chemmol/99122203.html
Chemenu
CM110205
http://www.chemenu.com/products/CM110205
Chemspace
CSSB00000185803
https://chem-space.com/CSSB00000185803
Clearsynth
CS-T-03461
https://www.clearsynth.com/en/CST03461.html
Debye Scientific
DB-054818
http://www.debyesci.com/cas_65-49-6.html
Enamine
Z90121065
https://www.enaminestore.com/catalog/Z90121065
Finetech
FT-0689453
http://www.finetechnology-ind.com/prod/detail/pub/133-15-3.html
Finetech
FT-0617609
http://www.finetechnology-ind.com/prod/detail/pub/65-49-6.html
Glentham Life Sciences
GM8827
http://www.glentham.com/products/product/GM8827/
Hairui
HR133954
http://www.hairuichem.com/en/product/65-49-6.html
LGC Standards
DRE-C10227010
https://www.lgcstandards.com/US/en/p/DRE-C10227010
Lab Network
LN00175003
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN00175003
Matrix Scientific
75166
https://www.matrixscientific.com/075166.html
MedChem Express
HY-I0447
https://www.medchemexpress.com/4-aminosalicylic-acid.html
Molcore
CS22593
https://www.molcore.com/product/65-49-6
Oakwood
78671
http://www.oakwoodchemical.com/ProductsList.aspx?CategoryID=-2&txtSearch=63845&ExtHyperLink=1
Otava
2829520
https://search.otavachemicals.com/#!/search?query=2829520&type=code&base=dbb
Parchem
2487
http://www.parchem.com/chemical-supplier-distributor/4-amino-Salicylic-acid-004064.aspx
Parchem
31862
http://www.parchem.com/chemical-supplier-distributor/Salicylic-Acid-USP-021862.aspx
Renno Tech
RP21704
http://www.rennotech.com/product_show.asp?id=27414
Sigma-Aldrich
A79604_ALDRICH
https://www.sigmaaldrich.com/catalog/product/aldrich/a79604?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
PHR1746_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/phr1746?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
1026401_USP
https://www.sigmaaldrich.com/catalog/product/usp/1026401?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
V900740_VETEC
https://www.sigmaaldrich.com/catalog/product/vetec/v900740?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sinfoo Biotech
S001491
http://www.sinfoobiotech.com/product/1004889
Smolecule
S518644
http://www.smolecule.com/products/s518644
TCI (Tokyo Chemical Industry)
A0420
http://www.tcichemicals.com/eshop/en/us/commodity/A0420/index.html
THE BioTek
bt-259572
https://www.thebiotek.com/product/inhibitors/bt-259572
Vitas-M Laboratory
BBL013175
http://www.request.vitasmlab.biz/index.php?option=com_search_stk&Itemid=22&stk=BBL013175&?utm_source=pubchem&utm_medium=p_search_link&utm_campaign=pubchem_search&utm_content=pubchem_slink
VladaChem
VL264995-100G
https://www.vladachem.com/product.php?products=65-49-6
Yuhao Chemical
XJ0046
http://www.chemyuhao.com/65-49-6.html
abcr GmbH
AB131475
http://www.abcr.com/shop/en/AB131475
eNovation Chemicals
D379680
http://www.enovationchem.com/productDetails.asp?productID=D379680
eNovation Chemicals
D590479
https://enovationchem.com/ProductDetails.asp?ProductID=D590479
eNovation Chemicals
D401935
https://www.enovationchem.com/ProductDetails.asp?ProductID=D401935
eNovation Chemicals
D669867
https://www.enovationchem.com/ProductDetails.asp?ProductID=D669867
mcule
MCULE-4841633599
https://mcule.com/MCULE-4841633599/
PubMed

PubMed

TitleDatePubMed
Tuberculostatic derivatives of rho-aminobenzoic acid; esters and amides of 4-aminosalicylic acid.
1948
A procedure for the determination of 4-aminosalicylic acid (p-aminosalicylic acid) in blood and in urine.
1949 Feb
[Ethers of 4-aminosalicylic acid].
1953 May
A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis.
1984
4-Aminosalicylic acid retention enemas in treatment of distal colitis.
1987 Jul
Experience with topical administration of 4-aminosalicylic acid in ulcerative colitis.
1989 Feb
4-Aminosalicylic acid enemas for ulcerative colitis.
1989 Feb 25
Luminal concentrations of orally ingested 4-aminosalicylic acid as determined by in-vivo equilibrium dialysis.
1990 Dec
Double blind, controlled trial of 4-aminosalicylic acid and prednisolone enemas in distal ulcerative colitis.
1992 Jul
A prospective randomized double blind trial comparing prednisolone and 4-aminosalicylic acid enemas in acute distal ulcerative colitis.
1992 Mar-Apr
Patents

Patents

006811-001
6

Sample Use Guides

In Vivo Use Guide
The adult dosage of four grams (one packet) three times per day or correspondingly smaller doses in children.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: The developed nanodelivery formulation based on para-aminosalicylic acid (PAS) and zinc layered hydroxide has a fourfold higher efficacy of PAS against mycobacterium tuberculosis with a minimum inhibitory concentration (MIC) found to be at 1.40 ug/mL compared to the free drug PAS with a MIC of 5.0 ug/mL.
5.0 ug/mL MIC against mycobacterium tuberculosis.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:06:21 GMT 2023
Edited
by admin
on Fri Dec 15 15:06:21 GMT 2023
Record UNII
5B2658E0N2
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AMINOSALICYLIC ACID
HSDB   MART.   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
Systematic Name English
PARA-AMINOSALICYLIC ACID
Systematic Name English
4-AMINO-2-HYDROXYBENZOIC ACID
Systematic Name English
AMINOSALICYLIC ACID [USP MONOGRAPH]
Common Name English
Aminosalicylic acid [WHO-DD]
Common Name English
P-AMINOSALICYLIC ACID [MI]
Common Name English
BENZOIC ACID, 4-AMINO-2-HYDROXY-
Common Name English
AMINOSALICYLIC ACID [ORANGE BOOK]
Common Name English
AMINOSALICYLATE
Systematic Name English
NEOPASALATE COMPONENT AMINOSALICYLIC ACID
Common Name English
AMINOSALICYLIC ACID COMPONENT OF NEOPASALATE
Common Name English
P-AMINOSALICYLIC ACID
MI  
Common Name English
AMINOSALICYLIC ACID [MART.]
Common Name English
4-Aminosalicylic acid
Systematic Name English
AMINOSALICYLIC ACID [HSDB]
Common Name English
PASER
Brand Name English
MESALAZINE IMPURITY E [EP IMPURITY]
Common Name English
PARASAL
Brand Name English
PAS
Common Name English
AMINOSALICYLIC ACID [VANDF]
Common Name English
NSC-2083
Code English
AMINOSALICYLIC ACID [USP-RS]
Common Name English
Classification Tree Code System Code
EU-Orphan Drug EU/3/10/826
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
WHO-ATC J04AA01
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
FDA ORPHAN DRUG 65792
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
LIVERTOX 42
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
WHO-ATC J04AA02
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
FDA ORPHAN DRUG 220506
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 6.2.4
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
WHO-VATC QJ04AA01
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
WHO-ATC J04AA03
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
NCI_THESAURUS C280
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
FDA ORPHAN DRUG 37989
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
Code System Code Type Description
RS_ITEM_NUM
1026401
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-613-5
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
NSC
2083
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
DRUG CENTRAL
2050
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
FDA UNII
5B2658E0N2
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
MESH
D010131
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
RXCUI
113374
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
ALTERNATIVE
DRUG BANK
DB00233
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
MERCK INDEX
m1743
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY Merck Index
HSDB
3203
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
ChEMBL
CHEMBL1169
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
CHEBI
27565
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
SMS_ID
100000092424
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
LACTMED
Aminosalicylic Acid
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
PUBCHEM
4649
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
RXCUI
7833
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
EVMPD
SUB12862MIG
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
CAS
65-49-6
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
WIKIPEDIA
4-AMINOSALICYLIC ACID
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
EPA CompTox
DTXSID2022591
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
NCI_THESAURUS
C47394
Created by admin on Fri Dec 15 15:06:21 GMT 2023 , Edited by admin on Fri Dec 15 15:06:21 GMT 2023
PRIMARY
Related Record Type Details
Structure of AMINOSALICYLATE SODIUM
SALT/SOLVATE -> PARENT
Structure of CALCIUM PARAAMINOSALICYLATE HEMIHEPTAHYDRATE
SALT/SOLVATE -> PARENT
Structure of PASINIAZID
SALT/SOLVATE -> PARENT
Structure of PASOMYCIN
SALT/SOLVATE -> PARENT
Structure of PASCAINE
SALT/SOLVATE -> PARENT
Structure of AMINOSALICYLATE CALCIUM ANHYDROUS
SALT/SOLVATE -> PARENT
Structure of POTASSIUM AMINOSALICYLATE
SALT/SOLVATE -> PARENT
Structure of AMINOSALICYLATE CALCIUM
SALT/SOLVATE -> PARENT
Structure of AMINOSALICYLATE SODIUM ANHYDROUS
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of MESALAMINE
PARENT -> IMPURITY
Correction factors: for the calculation of contents, multiply the peak areas by 1.3
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of AMINOSALICYLIC ACID
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966